DCB Newsletter #9: Looking back – what happened to the DCB Open Innovation Challenge winner 2021?
To be a winner at the DCB Open Innovation Challenge means receiving a massive forward push, in terms of budget and in-kind support. But what happens after enjoying the successful moment? We wanted to know and that’s why we’ve created this new series within our newsletter. This time with Nicolas Elvemo (CEO) and Lukas Scherer (CTO) from GlucoSet. Enjoy the read!
How are things going with you & GlucoSet at the moment, what is the status and what are you currently working on?
GlucoSet: We have started to work with the manufacturing partners to finish the design including all manufacturing aspects. This is a big step for the company since we suddenly do not think in single sensors but in 100’000 sensors volume. Furthermore we started to write patents, which we plan to submit in the upcoming months.
On the financial side, we just received exciting news from the European commission funding GlucoSet with €5.5M, this blended finance from the EU helps us tremendously to filling up the Series A financing round.
What has changed since the Challenge / how did the Challenge support you?
GlucoSet: The challenge helped us to widen the Network in many areas: DCB helped us to get in touch with real experts in developing glucose sensing systems, to learn from their experience is invaluable for a startup like ours developing such a multidisciplinary product. Furthermore we could widen our network with experts in the field of regulations, which allows us to get a second opinion and we were also given many contacts of manufacturing and business partners. Last but not least, we would like to mention the connection to DCB itself; we just submitted a grant application with one of the DCB professors.
It is very noticeable that the prize increased the visibility to investors, and to the MedTech society.
On the financial side, we just received exciting news from the European commission funding GlucoSet with €5.5M, this blended finance from the EU helps us tremendously to filling up the Series A financing round.
What is to come in the upcoming months?
GlucoSet: We still have some technical problems to solve, and we slowly start to make the company ready to enter into the regulated development phase. We look very much forward to soon having a first monitor prototype with a running graphical user interface we can connect with the sensors.
Thanks so much for reading and we’ll provide you with the next episode of this series soon!
Dieser Beitrag wurde zuerst als Newsletter auf LinkedIn publiziert. Klicke hier um den Artikel auf LinkedIn zu lesen.
Neuigkeiten
DCB Newsletter #5/24: INSIDE DCB – Our Milestones in 2024
Dear DCB community – as we approach the end of this year, we want to take the opportunity to look back on our team’s...
DCB Newsletter #4/24: IT’S A WRAP! A Recap of the 2024 DCB Open Innovation Challenge
Dear community – long time no see! At the height of Diabetes Awareness Month Novemver, we are happy to now provide you...
DCB Newsletter #3/24: The DCB Open Innovation Challenge is back!
Dear community, it's that time of the year again...the DCB Open Innovation Challenge is back – and this time, it's...
DCB Research AG
Freiburgstrasse 3
3010 Bern
Switzerland